[nbn Domestic and Foreign News] January 25, 2019
Miracell, a stem cell company, announced on the 25th that it has developed a stem cell isolation system that rivals world-class technology.
This system, which is capable of isolating and concentrating stem cells and immune cells from bone marrow and blood, received approval from the Ministry of Food and Drug Safety in the latter half of last year and is currently being sold to hospitals and clinics.
Miracell’s recently launched bone marrow-derived stem cell and immune cell isolation/concentration system, currently available worldwide, holds significant global significance, with only three or four systems currently on the market.
This development is expected to further narrow the accessibility of demanding procedures using bone marrow-derived cells.
With the growing importance of cell-focused systems, which have traditionally relied on blood-derived cell isolation/concentration systems or platelet-rich plasma (PRP),
we anticipate increased utilization in hospitals and clinics both domestically and internationally.
The currently available stem cell and immune cell separation/concentration system can be used to treat conditions previously designated as new medical technologies by Miracell Co., Ltd., such as cartilage defects, critical limb ischemia, acute myocardial infarction, and dissecting osteoarthritis of the knee joint. It can also be used as a limited medical technology for conditions such as diabetic critical limb ischemia and nonunion/delayed union. Miracell Co., Ltd. has excellent technological prowess with 6 registered technology patents and 8 patent applications, and currently has patents registered for a decanting kit that facilitates component-specific separation and extraction (2018.06.28), a centrifugal container that facilitates component-specific separation and extraction (2018.09.06, 2018.10.18), a swing rotor assembly for centrifugal separators (2018.08.23), a centrifugal container (2018.08.29), and a dual-wavelength skin treatment laser device (2010.07.21). In addition, a centrifugal container that facilitates component-specific separation and extraction (2017.07.17), a centrifugal kit that facilitates sample collection and component-specific separation (2017.07.17), a bucket for centrifugal separators (2018.07.20), and a component separation device for centrifugal separators. Patent applications include a floater (January 9, 2018), a centrifuge container (March 30, 2018), a vending machine for personalized cosmetics manufacturing using AI (May 8, 2018), and a centrifuge equipped with a charging device (July 20, 2018).
As stem cells continue to receive attention in the field of regenerative medicine, the development of medical equipment that efficiently separates and concentrates stem cells is of great global significance.
This technological development is expected to brighten Miracell’s prospects for future expansion into overseas markets.
Jang Ik-kyung jik7522@nbnnews.co.kr